Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study

Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study

Toussaint Rouamba,1,* Houreratou Barry,2,* Esperance Ouédraogo,1 Marc Christian Tahita,1 Nobila Valentin Yaméogo,3 Armel Poda,4 Arnaud Eric Diendéré,5 Abdoul-Salam Ouedraogo,4 Innocent Valea,1 Amariane M Koné,2 Cherileila Thiombiano,2 Isidore Traoré,2 Zekiba Tarnagda,1 Serge A Sawado...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rouamba T, Barry H, Ouédraogo E, Tahita MC, Yaméogo NV, Poda A, Diendéré AE, Ouedraogo AS, Valea I, Koné AM, Thiombiano C, Traoré I, Tarnagda Z, Sawadogo SA, Gansané Z, Kambiré Y, Sanou I, Barro-Traoré F, Drabo MK, Tinto H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
sars-cov-2
chloroquine
hydroxychloroquine
azithromycin
safety
virus shedding
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/7f632ff23a39418aa3a1936be47a35e1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7f632ff23a39418aa3a1936be47a35e1
record_format dspace
institution DOAJ
collection DOAJ
language EN
topic sars-cov-2
chloroquine
hydroxychloroquine
azithromycin
safety
virus shedding
Therapeutics. Pharmacology
RM1-950
spellingShingle sars-cov-2
chloroquine
hydroxychloroquine
azithromycin
safety
virus shedding
Therapeutics. Pharmacology
RM1-950
Rouamba T
Barry H
Ouédraogo E
Tahita MC
Yaméogo NV
Poda A
Diendéré AE
Ouedraogo AS
Valea I
Koné AM
Thiombiano C
Traoré I
Tarnagda Z
Sawadogo SA
Gansané Z
Kambiré Y
Sanou I
Barro-Traoré F
Drabo MK
Tinto H
Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
description Toussaint Rouamba,1,* Houreratou Barry,2,* Esperance Ouédraogo,1 Marc Christian Tahita,1 Nobila Valentin Yaméogo,3 Armel Poda,4 Arnaud Eric Diendéré,5 Abdoul-Salam Ouedraogo,4 Innocent Valea,1 Amariane M Koné,2 Cherileila Thiombiano,2 Isidore Traoré,2 Zekiba Tarnagda,1 Serge A Sawadogo,6 Zakaria Gansané,7 Yibar Kambiré,8 Idrissa Sanou,8 Fatou Barro-Traoré,8 Maxime K Drabo,1 Halidou Tinto1 On behalf of the CHLORAZ Study Group1Institut de Recherche en Sciences de la Santé (CNRST-IRSS), Nanoro, Burkina Faso; 2Institut National de Santé Publique, Centre Muraz, Bobo-Dioulasso, Burkina Faso; 3Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso; 4Centre Hospitalier Universitaire Sourou Sanon, Bobo-Dioulasso, Burkina Faso; 5Centre Hospitalier Universitaire de Bogodogo, Ouagadougou, Burkina Faso; 6Centre PrïmO Nelson Mandela (Promotion de la Recherche et de l’Innovation en Immunologie Médicale de Ouagadougou), Ouagadougou, Burkina Faso; 7Clinical Monitoring in Africa-Clinical Research Organization, Ouagadougou, Burkina Faso; 8Centre Hospitalier Universitaire de Tengandogo, Ouagadougou, Burkina Faso*These authors contributed equally to this workCorrespondence: Toussaint RouambaInstitut de Recherche en Sciences de la Santé (CNRST-IRSS), 528, Avenue Kumda-Yoore, BP 218 Ouagadougou CMS 11, Ouagadougou, Nanoro, Burkina FasoTel +226 666 532 04Email rouambatoussaint@gmail.comIntroduction: Though chloroquine derivatives are used in the treatment of coronavirus disease 2019 (COVID-19) in many countries worldwide, doubts remain about the safety and efficacy of these drugs, especially in African communities where published data are scarce.Methods: We conducted an observational prospective cohort study from April 24 to September 03, 2020, in Burkina Faso to assess (as primary outcome) the clinical, biological, and cardiac (electrocardiographic) safety of chloroquine or hydroxychloroquine plus azithromycin administered to COVID-19 patients. The main secondary outcomes were all-cause mortality and median time of viral clearance.Results: A total of 153 patients were enrolled and followed for 21 days. Among patients who took at least one dose of chloroquine or hydroxychloroquine (90.1% [138/153]), few clinical adverse events were reported and were mainly rash/pruritus, diarrhea, chest pain, and palpitations. No statistically significant increase in hepatic, renal, and hematological parameters or electrolyte disorders were reported. However, there was a significant increase in the QTc value without exceeding 500ms, especially in those who received chloroquine phosphate. Three adverse events of special interest classified as serious (known from chloroquine derivatives) were recorded namely pruritus, paresthesia, and drowsiness. One case of death occurred. The average onset of SARS-CoV-2 PCR negativity was estimated at 7.0 (95% CI: 5.0– 10.0) days.Conclusion: Hydroxychloroquine appeared to be well tolerated in treated COVID-19 patients in Burkina Faso. In the absence of a robust methodological approach that could generate a high level of scientific evidence, our results could at least contribute to guide health decisions that should be made based on different sources of scientific evidence including those from our study.Keywords: SARS-CoV-2, chloroquine, hydroxychloroquine, azithromycin, safety, virus shedding
format article
author Rouamba T
Barry H
Ouédraogo E
Tahita MC
Yaméogo NV
Poda A
Diendéré AE
Ouedraogo AS
Valea I
Koné AM
Thiombiano C
Traoré I
Tarnagda Z
Sawadogo SA
Gansané Z
Kambiré Y
Sanou I
Barro-Traoré F
Drabo MK
Tinto H
author_facet Rouamba T
Barry H
Ouédraogo E
Tahita MC
Yaméogo NV
Poda A
Diendéré AE
Ouedraogo AS
Valea I
Koné AM
Thiombiano C
Traoré I
Tarnagda Z
Sawadogo SA
Gansané Z
Kambiré Y
Sanou I
Barro-Traoré F
Drabo MK
Tinto H
author_sort Rouamba T
title Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
title_short Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
title_full Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
title_fullStr Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
title_full_unstemmed Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
title_sort safety of chloroquine or hydroxychloroquine plus azithromycin for the treatment of covid-19 patients in burkina faso: an observational prospective cohort study
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/7f632ff23a39418aa3a1936be47a35e1
work_keys_str_mv AT rouambat safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT barryh safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT ouedraogoe safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT tahitamc safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT yameogonv safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT podaa safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT diendereae safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT ouedraogoas safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT valeai safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT koneam safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT thiombianoc safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT traorei safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT tarnagdaz safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT sawadogosa safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT gansanez safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT kambirey safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT sanoui safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT barrotraoref safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT drabomk safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
AT tintoh safetyofchloroquineorhydroxychloroquineplusazithromycinforthetreatmentofcovid19patientsinburkinafasoanobservationalprospectivecohortstudy
_version_ 1718426249991290880
spelling oai:doaj.org-article:7f632ff23a39418aa3a1936be47a35e12021-11-16T18:47:50ZSafety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study1178-203Xhttps://doaj.org/article/7f632ff23a39418aa3a1936be47a35e12021-11-01T00:00:00Zhttps://www.dovepress.com/safety-of-chloroquine-or-hydroxychloroquine-plus-azithromycin-for-the--peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XToussaint Rouamba,1,* Houreratou Barry,2,* Esperance Ouédraogo,1 Marc Christian Tahita,1 Nobila Valentin Yaméogo,3 Armel Poda,4 Arnaud Eric Diendéré,5 Abdoul-Salam Ouedraogo,4 Innocent Valea,1 Amariane M Koné,2 Cherileila Thiombiano,2 Isidore Traoré,2 Zekiba Tarnagda,1 Serge A Sawadogo,6 Zakaria Gansané,7 Yibar Kambiré,8 Idrissa Sanou,8 Fatou Barro-Traoré,8 Maxime K Drabo,1 Halidou Tinto1 On behalf of the CHLORAZ Study Group1Institut de Recherche en Sciences de la Santé (CNRST-IRSS), Nanoro, Burkina Faso; 2Institut National de Santé Publique, Centre Muraz, Bobo-Dioulasso, Burkina Faso; 3Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso; 4Centre Hospitalier Universitaire Sourou Sanon, Bobo-Dioulasso, Burkina Faso; 5Centre Hospitalier Universitaire de Bogodogo, Ouagadougou, Burkina Faso; 6Centre PrïmO Nelson Mandela (Promotion de la Recherche et de l’Innovation en Immunologie Médicale de Ouagadougou), Ouagadougou, Burkina Faso; 7Clinical Monitoring in Africa-Clinical Research Organization, Ouagadougou, Burkina Faso; 8Centre Hospitalier Universitaire de Tengandogo, Ouagadougou, Burkina Faso*These authors contributed equally to this workCorrespondence: Toussaint RouambaInstitut de Recherche en Sciences de la Santé (CNRST-IRSS), 528, Avenue Kumda-Yoore, BP 218 Ouagadougou CMS 11, Ouagadougou, Nanoro, Burkina FasoTel +226 666 532 04Email rouambatoussaint@gmail.comIntroduction: Though chloroquine derivatives are used in the treatment of coronavirus disease 2019 (COVID-19) in many countries worldwide, doubts remain about the safety and efficacy of these drugs, especially in African communities where published data are scarce.Methods: We conducted an observational prospective cohort study from April 24 to September 03, 2020, in Burkina Faso to assess (as primary outcome) the clinical, biological, and cardiac (electrocardiographic) safety of chloroquine or hydroxychloroquine plus azithromycin administered to COVID-19 patients. The main secondary outcomes were all-cause mortality and median time of viral clearance.Results: A total of 153 patients were enrolled and followed for 21 days. Among patients who took at least one dose of chloroquine or hydroxychloroquine (90.1% [138/153]), few clinical adverse events were reported and were mainly rash/pruritus, diarrhea, chest pain, and palpitations. No statistically significant increase in hepatic, renal, and hematological parameters or electrolyte disorders were reported. However, there was a significant increase in the QTc value without exceeding 500ms, especially in those who received chloroquine phosphate. Three adverse events of special interest classified as serious (known from chloroquine derivatives) were recorded namely pruritus, paresthesia, and drowsiness. One case of death occurred. The average onset of SARS-CoV-2 PCR negativity was estimated at 7.0 (95% CI: 5.0– 10.0) days.Conclusion: Hydroxychloroquine appeared to be well tolerated in treated COVID-19 patients in Burkina Faso. In the absence of a robust methodological approach that could generate a high level of scientific evidence, our results could at least contribute to guide health decisions that should be made based on different sources of scientific evidence including those from our study.Keywords: SARS-CoV-2, chloroquine, hydroxychloroquine, azithromycin, safety, virus sheddingRouamba TBarry HOuédraogo ETahita MCYaméogo NVPoda ADiendéré AEOuedraogo ASValea IKoné AMThiombiano CTraoré ITarnagda ZSawadogo SAGansané ZKambiré YSanou IBarro-Traoré FDrabo MKTinto HDove Medical Pressarticlesars-cov-2chloroquinehydroxychloroquineazithromycinsafetyvirus sheddingTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 1187-1198 (2021)

Ejemplares similares